Before the Jury Is out on Cinacalcet's Cardiovascular Effects in Hemodialysis Patients: Is Troponin a Missing Link?
2014
Raised levels of the cardiac biomarker, Troponin I, are frequently encountered in hemodialysis
patients and appear to be prognostic indicators for cardiovascular risk. Though
evidence suggests that control of secondary hyperparathyroidism may reduce
cardiac endpoints, the effect of the calcimimetic agent, cinacalcet, remains controversial. This retrospective
study aimed at evaluating troponin levels in hemodialysis patients with severe
secondary hyper parathyroidism (SHPT) who
are on cinacalcet vs controls on conventional treatment. In addition, clinical
outcomes including all-cause, cardiovascular morbidity and mortality were
compared among both groups. A decline in Troponin I levels was observed in the cinacalcet
group, this however was not translated clinically into improved survival. In
fact, all-cause and cardiac mortality was similar in the two groups.
Conversely, comparison of the incidence of cardiovascular events revealed lower
rates in the cinacalcet group including cardiac, cerebral and peripheral
vascular complications. Given some of our study limitations, further long-term,
placebo-controlled trials are necessary to definitively establish the effect of
cinacalet on cardiac biomarkers and ultimately its impact on clinical outcomes.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
27
References
1
Citations
NaN
KQI